Business Wire

CSC Adds Two Industry Leaders in Luxembourg; Secures Fund Administration and Depositary Licenses for Additional Services

21.9.2021 11:00:00 EEST | Business Wire | Press release

Share

CSC, the world’s leading provider of business, legal, tax, and digital brand services, has significantly expanded its operations in Luxembourg by securing new fund administration and depositary licenses and adding two experienced executives to help lead its growth in the market. This further extends CSC’s European fund administration and depositary offerings.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005284/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Yves Cheret (Photo: Business Wire)

With these key hires, clients will benefit from the addition of more than 30 years of combined industry expertise to CSC’s long-standing service offerings, including a range of alternative investment, capital markets, and corporate solutions. In addition, these new licenses will open new and essential services to clients in Luxembourg, yet another key European financial center in CSC’s growing footprint.

Veteran talent, local expertise

Pierre Mifsud joins as managing director for depositary services for CSC Global Financial Markets (GFM), while Yves Cheret comes aboard as managing director of fund administration for CSC GFM. Both will work with Laurent Bélik, managing director of Capital Markets Europe, who is responsible for general management, including finance and operations in Luxembourg.

“Pierre and Yves will add tremendous value for our clients,” said Bélik. “Because CSC is privately owned, we can invest additional time and effort to build long-term relationships with our clients and focus on the complexities of their unique needs and markets. We take the same approach with our employees, which has allowed us to develop and retain top industry talent to provide clients with the knowledge base, stability, and world-class service that CSC is known for, both locally and around the world.”

Mifsud comes to CSC with more than 15 years of experience in the alternative funds industry, with a focus on private equity, real estate, venture capital, infrastructure, and debt funds. Mifsud previously held leadership roles at Edmond de Rothschild (Europe) S.A., Citco Bank Nederland N.V. Luxembourg Branch, and Quintet Luxembourg.

“The number of funds domiciled in Luxembourg surpasses all other European markets, so the ability to provide depositary services for alternative assets allows CSC to give clients greater flexibility whether they are based here or somewhere else,” said Mifsud.

Cheret, meanwhile, has held senior positions in the alternative investment fund industry in Luxembourg for companies such as Alter Domus, Arendt Services, and Ocorian. He is fluent in five languages and is a qualified chartered accountant.

“I look forward to working with Laurent and Pierre and the rest of our talented, multilingual team in Luxembourg to help our clients navigate the increasingly complex environment they face,” said Cheret. “Whether they need fund administration or depositary services or both, CSC’s centralized team offers clients global reach and unrivaled service quality that is committed to supporting their business.”

About CSC

CSC is a leading provider of specialized administration services to alternative asset managers across a range of fund strategies, capital markets participants in both public and private markets, and corporations requiring fiduciary and governance support. We are the unwavering partner for 90% of the Fortune 500®, nearly 10,000 law firms, and more than 3,000 financial institutions. CSC’s Global Financial Markets professionals are located in key financial centers across the U.S., Europe, and Asia-Pacific. We are a global company capable of conducting transactions wherever our clients are―and we accomplish that by deploying experts in every business we serve. For more information about CSC’s services, visit cscgfm.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jeff Lyons
Public Relations Manager
(302) 636-5401 x65519
jeff.lyons@cscglobal.com
CSC News Room

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release

Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye